_0_0.png){kind=logo}
Our vision: individualize cancer medicine
Our Responsibility
Corporate Social Responsibility (CSR) at BioNTech
BioNTech is a next-generation immunotherapy company pioneering novel therapies for cancer, infectious and other serious diseases. Our COVID- 19 vaccine is an important milestone. The aim of the Company and its core business model is to provide these novel therapies to patients worldwide and thus, help to improve their lives.
Our core values form the basis of everything we do: we are innovative, passionate and united. Throughout our work we are committed to being transparent, acting with integrity, protecting the environment and respecting human rights. These values form the unchanging basis of our work and, above all, our very own expectations of ourselves.
We have signed the United Nations Global Compact and support the Sustainable Development Goals (SDGs). In particular, our work contributes to the third SDG 3 – the promotion of good health and well-being for all people at all ages.
In March 2021, we published our first Sustainability Report. This is a milestone for us as a company. It shows us where we stand and in which areas we need to improve. For our stakeholders this report offers a first impression of our wider responsibility.
Group-wide management of Corporate Social Responsibility
As a biotech company with research and – since the end of 2020 – commercial manufacturing, we bear responsibility not only for our business, but also for the way our business is conducted. Ultimate responsibility for all CSR topics rests with the entire Management Board, which is supported strategically by the CSR Steering Board and operationally by the CSR Team.
Read in the Sustainability Report 2020 how we are anchoring responsibility in our core business.
The most important topics of CSR
BioNTech identified the most important and the material CSR topics through a multi-step and cross-functional process. This was based on the analyses of relevant sustainability standards (e. g., GRI, SASB, NASDAQ ESG Reporting Guide) and benchmarks (e. g., the Pharmaceutical Supply Chain Initiative PSCI, Company benchmarks) as well as on structured internal interviews with BioNTech’s top executives.
Read in the Sustainability Report 2020 how the perspectives of various stakeholder groups were taken into account.
With the first emergency use approval of the COVID-19 vaccine worldwide on December 2, 2020, and its commercial production, society’s perception of BioNTech has changed significantly.
Read in the Sustainability Report 2020 how we address the expectations of patients, investors, employees and business partners, climate protectors and NGOs campaigning for fair and equitable global access to COVID-19 vaccines.
The Management Board and Supervisory Board work together for the benefit of BioNTech. They pursue the objective of sustainable value creation and have the interests of our shareholders, employees and other stakeholders equally in mind. These principles demand not only legal compliance but also ethically sound and responsible conduct.
Read in the Sustainability Report 2020 how responsible corporate governance ensures BioNTech's resilience.
By the end of 2020, BioNTech had 2,407 employees from over 60 nations. And we continue to grow. As a biotechnology company, we are in intense competition for employees. After all, they form the basis of our corporate success.
Our human resources department therefore ensures that specialists are retained in the company, new talent is recruited and that we have global integration of our teams across all subsidiaries – new and old. In addition, the Sustainable Growth & Culture working group was established. Its aim is to actively shaping a culture that promotes sustainable growth in the interests of all stakeholders. As an attractive employer, we also ensure the highest occupational safety standards for our employees.
Read in our Sustainability Report 2020 how we are shaping a sustainable corporate culture for growth.
The work we do has an impact on the environment. Production processes, the operation of R&D laboratories and planned major infrastructure and construction projects result in energy need, consumption of raw and auxiliary materials and the generation of waste.
We follow our successful path of growth in a Paris-aligned and environmentally conscious way and strive to be climate neutral by 2030.
Read in our Sustainability Report 2020 how we are creating value and growth within planetary boundaries.
We are convinced that BioNTech has a responsibility as a corporate citizen. We meet this responsibility with our corporate citizenship concept. The material topic "Caring for Patients" will be addressed and developed within this framework. In close cooperation with our business areas, we aim to use and promote the skills of our employees in a targeted and effective way through corporate volunteering activities. We attribute great importance to shaping our social commitment in a sustainable manner and in line with our corporate values.
OUR MATERIALITY MATRIX
The CSR program as a cross-divisional management tool
For all relevant issues identified in the materiality process, measures, objectives and implementation deadlines were described in the CSR program. By linking the materiality analysis to the CSR program, we ensure that all relevant stakeholder interests are taken into account.
Read our Sustainability Report 2020 to find out to what extent we met our CSR targets in 2020.
